NO20060219L - Forbindelser - Google Patents
ForbindelserInfo
- Publication number
- NO20060219L NO20060219L NO20060219A NO20060219A NO20060219L NO 20060219 L NO20060219 L NO 20060219L NO 20060219 A NO20060219 A NO 20060219A NO 20060219 A NO20060219 A NO 20060219A NO 20060219 L NO20060219 L NO 20060219L
- Authority
- NO
- Norway
- Prior art keywords
- ring
- optionally substituted
- heterobycyclic
- group
- unsaturated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Det beskrives en forbindelse av formel (I) hvor ring A og ring B er, (1) ring A er en valgfritt substituert umettet monosyklisk heterosyklisk ring, og ring B er en valgfritt substituert umettet monosyklisk heterosyklisk ring, en valgfritt substituert umettet fusjonert heterobisyklisk ring, eller en valgfritt substituert benzennng, (2) ring A er en valgfritt substituert benzenrmg, og ring B er en valgfritt substituert umettet monosyklisk heterosyklisk ring, en valgfritt substituert umettet fusjonert heterobisyklisk ring, eller en valgfritt substituert benzennng, eller (3) ring A er en valgfritt substituert umettet fusjonert heterobisyklisk ring, hvor -NR- gruppen og -CH2- gruppen er begge på den samme ring av den umettede fusjonerte heterobisykhske ring, og ring B er en valgfritt substituert monosyklisk umettet heterosyklisk ring, en valgfritt substituert umettet fusjonert heterobisyklisk ring, eller en valgfritt substituert benzenrmg, og R er et hydrogenatom, en lavere alkylgruppe, en lavere alkanoylgruppe eller en lavere alkoksykarbonylgruppe, eller et farmasøytisk akseptabelt salt derav, eller et prodrug derav
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49152303P | 2003-08-01 | 2003-08-01 | |
| PCT/JP2004/011311 WO2005012321A1 (en) | 2003-08-01 | 2004-07-30 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20060219L true NO20060219L (no) | 2006-04-28 |
| NO333679B1 NO333679B1 (no) | 2013-08-05 |
Family
ID=34115512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060219A NO333679B1 (no) | 2003-08-01 | 2006-01-16 | Forbindelse eller farmasoytisk salt derav, samt anvendelser og fremgangsmate for fremstilling av samme |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7521430B2 (no) |
| EP (1) | EP1654269B1 (no) |
| JP (1) | JP4717811B2 (no) |
| KR (1) | KR101101500B1 (no) |
| CN (2) | CN102060888A (no) |
| AU (1) | AU2004260760B2 (no) |
| BR (1) | BRPI0413233A (no) |
| CA (1) | CA2534022C (no) |
| EA (1) | EA011025B1 (no) |
| ES (1) | ES2527053T3 (no) |
| IL (1) | IL173051A (no) |
| MX (1) | MXPA06001273A (no) |
| NO (1) | NO333679B1 (no) |
| NZ (1) | NZ545305A (no) |
| TW (1) | TWI377209B (no) |
| UA (5) | UA86042C2 (no) |
| WO (1) | WO2005012321A1 (no) |
| ZA (2) | ZA200601686B (no) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2514756B1 (en) * | 2003-08-01 | 2014-12-17 | Mitsubishi Tanabe Pharma Corporation | Novel compounds having inhibitory activity against sodium-dependant glucose transporter |
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| MY147375A (en) | 2005-01-31 | 2012-11-30 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| JP5073948B2 (ja) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| US7666845B2 (en) * | 2006-12-04 | 2010-02-23 | Janssen Pharmaceutica N.V. | Compounds having inhibitory activity against sodium-dependent glucose transporter |
| UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
| HUE035130T2 (en) | 2007-09-10 | 2018-05-02 | Janssen Pharmaceutica Nv | A method for preparing compounds useful as SGLT inhibitors |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| MX2010012656A (es) | 2008-05-22 | 2010-12-20 | Squibb Bristol Myers Co | Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo. |
| CN102149717B (zh) | 2008-08-28 | 2014-05-14 | 辉瑞大药厂 | 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物 |
| WO2010031813A1 (en) * | 2008-09-19 | 2010-03-25 | Novartis Ag | Glycoside derivatives and uses thereof |
| US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| DK2451797T3 (da) | 2009-07-10 | 2013-06-24 | Janssen Pharmaceutica Nv | Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen |
| EP2488515B1 (en) * | 2009-10-14 | 2017-01-04 | Janssen Pharmaceutica NV | Process for the preparation of compounds useful as inhibitors of sglt2 |
| PL2496583T3 (pl) | 2009-11-02 | 2015-04-30 | Pfizer | Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolowe |
| TWI599360B (zh) | 2010-05-11 | 2017-09-21 | 健生藥品公司 | 醫藥調配物 |
| RS55056B1 (sr) | 2011-04-13 | 2016-12-30 | Janssen Pharmaceutica Nv | Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2 |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| ES2835828T3 (es) * | 2013-02-26 | 2021-06-23 | Mitsubishi Tanabe Pharma Corp | Procedimiento para producir a-halo-tetraacilglucosa |
| CN103896930B (zh) * | 2014-04-02 | 2016-08-17 | 安徽联创生物医药股份有限公司 | 卡格列净半水合物药用晶型的制备方法 |
| ES2711804T3 (es) * | 2014-05-27 | 2019-05-07 | Glenmark Pharmaceuticals Ltd | Proceso para preparación de canagliflozina |
| CN104045673B (zh) * | 2014-06-06 | 2017-01-18 | 安徽省食品药品检验研究院 | 双‑三氮唑缀合的假二糖衍生物及其制备方法 |
| CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN106188022A (zh) * | 2015-04-30 | 2016-12-07 | 上海医药工业研究院 | 伊格列净的制备方法 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| ES3035734T3 (en) | 2017-11-30 | 2025-09-08 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| EP4315350A1 (en) | 2021-04-01 | 2024-02-07 | AstraZeneca UK Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
| WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
| TW202525278A (zh) | 2023-12-15 | 2025-07-01 | 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 | 治療慢性腎病及高血壓之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1075626B (de) * | 1960-02-18 | Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M | Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden | |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| TR200202200T2 (tr) | 2000-03-17 | 2002-12-23 | Kissei Pharmaceutical Co., Ltd. | Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler. |
| US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| CZ303544B6 (cs) * | 2000-09-29 | 2012-11-28 | Kissei Pharmaceutical Co., Ltd. | Glukopyranosyloxybenzylbenzenový derivát a farmaceutická kompozice s jeho obsahem |
| CA2429833A1 (en) * | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| HU228915B1 (en) | 2000-12-28 | 2013-06-28 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives and use thereof |
| TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| WO2003020737A1 (en) | 2001-09-05 | 2003-03-13 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2004
- 2004-07-29 UA UAA200605348A patent/UA86042C2/ru unknown
- 2004-07-30 JP JP2006519250A patent/JP4717811B2/ja not_active Expired - Fee Related
- 2004-07-30 BR BRPI0413233-5A patent/BRPI0413233A/pt not_active IP Right Cessation
- 2004-07-30 CA CA2534022A patent/CA2534022C/en not_active Expired - Fee Related
- 2004-07-30 UA UAA200605349A patent/UA86599C2/ru unknown
- 2004-07-30 EA EA200600348A patent/EA011025B1/ru not_active IP Right Cessation
- 2004-07-30 UA UAA200602256A patent/UA83377C2/uk unknown
- 2004-07-30 KR KR1020067002158A patent/KR101101500B1/ko not_active Expired - Fee Related
- 2004-07-30 UA UAA200605347A patent/UA85569C2/ru unknown
- 2004-07-30 TW TW093122844A patent/TWI377209B/zh not_active IP Right Cessation
- 2004-07-30 AU AU2004260760A patent/AU2004260760B2/en not_active Ceased
- 2004-07-30 MX MXPA06001273A patent/MXPA06001273A/es active IP Right Grant
- 2004-07-30 WO PCT/JP2004/011311 patent/WO2005012321A1/en not_active Ceased
- 2004-07-30 CN CN2010105463425A patent/CN102060888A/zh active Pending
- 2004-07-30 UA UAA200605346A patent/UA87991C2/ru unknown
- 2004-07-30 NZ NZ545305A patent/NZ545305A/en not_active IP Right Cessation
- 2004-07-30 EP EP04771313.6A patent/EP1654269B1/en not_active Expired - Lifetime
- 2004-07-30 US US10/566,585 patent/US7521430B2/en not_active Expired - Fee Related
- 2004-07-30 ES ES04771313.6T patent/ES2527053T3/es not_active Expired - Lifetime
- 2004-07-30 CN CNA2004800220063A patent/CN1829728A/zh active Pending
-
2006
- 2006-01-10 IL IL173051A patent/IL173051A/en not_active IP Right Cessation
- 2006-01-16 NO NO20060219A patent/NO333679B1/no not_active IP Right Cessation
- 2006-02-27 ZA ZA200601686A patent/ZA200601686B/en unknown
- 2006-05-15 ZA ZA200603880A patent/ZA200603880B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200601686B (en) | 2007-05-30 |
| IL173051A0 (en) | 2006-06-11 |
| EP1654269B1 (en) | 2014-10-15 |
| AU2004260760B2 (en) | 2009-08-13 |
| CN102060888A (zh) | 2011-05-18 |
| IL173051A (en) | 2012-06-28 |
| CA2534022A1 (en) | 2005-02-10 |
| NO333679B1 (no) | 2013-08-05 |
| ES2527053T3 (es) | 2015-01-20 |
| UA87991C2 (en) | 2009-09-10 |
| KR101101500B1 (ko) | 2012-01-03 |
| BRPI0413233A (pt) | 2006-10-03 |
| KR20060132539A (ko) | 2006-12-21 |
| EA200600348A1 (ru) | 2006-08-25 |
| US20070060545A1 (en) | 2007-03-15 |
| UA85569C2 (ru) | 2009-02-10 |
| CA2534022C (en) | 2012-10-02 |
| UA86042C2 (en) | 2009-03-25 |
| UA86599C2 (en) | 2009-05-12 |
| CN1829728A (zh) | 2006-09-06 |
| UA83377C2 (uk) | 2008-07-10 |
| TW200510440A (en) | 2005-03-16 |
| EP1654269A1 (en) | 2006-05-10 |
| WO2005012321A1 (en) | 2005-02-10 |
| NZ545305A (en) | 2008-11-28 |
| MXPA06001273A (es) | 2006-04-11 |
| ZA200603880B (en) | 2010-01-27 |
| TWI377209B (en) | 2012-11-21 |
| JP4717811B2 (ja) | 2011-07-06 |
| EA011025B1 (ru) | 2008-12-30 |
| US7521430B2 (en) | 2009-04-21 |
| AU2004260760A1 (en) | 2005-02-10 |
| JP2007518682A (ja) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060219L (no) | Forbindelser | |
| MXPA06001274A (es) | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. | |
| EA200600925A1 (ru) | Производные триазола в качестве антагонистов вазопрессина | |
| DE60107449D1 (de) | Substituierte aminopropoxyarylderivate als lxr agonisten | |
| AP1902A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| EA200601235A1 (ru) | Производные тиазола | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| ATE353870T1 (de) | Dibenzylaminverbindung und deren medizinische verwendung | |
| LU92113I2 (fr) | Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA) | |
| CY1112991T1 (el) | ΠΑΡΑΓΩΓΑ ΙΝΔΟΛΗΣ Ή ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΓΙΑ ΤΗ ΡΥΘΜΙΣΗ ΤΗΣ ΙκΒ ΚΙΝΑΣΗΣ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ | |
| DK1210344T3 (da) | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister | |
| NO986055D0 (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat | |
| EP1490371A4 (en) | TRICYCLIC COMPOUNDS BASED ON THIOPENE AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | |
| ATE424393T1 (de) | 3-substituierte 4-pyrimidonderivate | |
| UA81561C2 (en) | Use of n-arylhydrazine derivative and method for controlling non-crop pests | |
| DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
| MY140749A (en) | Novel piperidine compound | |
| ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
| GB0215392D0 (en) | Chemical compounds | |
| AR027035A1 (es) | Pirroles sustituidos | |
| NO20052023L (no) | Kalsium aktivert K kanal apner med hoy konduktans | |
| NO20023298D0 (no) | Nye imidazolderivater | |
| NO20063111L (no) | Fremgangsmate for fremstilling av tiazolpyrimidiner | |
| MY139258A (en) | Carbamoyl-type benzofuran derivatives | |
| UA85692C2 (ru) | Производные триазола как антагонисты вазопрессина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MITSUBISHI TANABE PHARMA CORP, JP |
|
| MM1K | Lapsed by not paying the annual fees |